688373 盟科药业
交易中 02-10 10:32:34
资讯
新帖
简况
每周股票复盘：盟科药业（688373）MRX-5获美临床试验许可
证券之星 · 02-01
每周股票复盘：盟科药业（688373）MRX-5获美临床试验许可
盟科药业：MRX-5片获美国FDA批准开展临床试验
证券之星 · 01-28
盟科药业：MRX-5片获美国FDA批准开展临床试验
每周股票复盘：盟科药业（688373）预计2025年亏损收窄至2.25亿至2.65亿元
证券之星 · 01-25
每周股票复盘：盟科药业（688373）预计2025年亏损收窄至2.25亿至2.65亿元
盟科药业（688373）披露2025年年度业绩预告，1月23日股价上涨1.86%
证券之星 · 01-23
盟科药业（688373）披露2025年年度业绩预告，1月23日股价上涨1.86%
盟科药业（688373）披露股东减持股份计划公告，1月14日股价上涨0.45%
证券之星 · 01-14
盟科药业（688373）披露股东减持股份计划公告，1月14日股价上涨0.45%
盟科药业（688373.SH）聘任卢亮为副总经理、郭萃为财务负责人
中金财经 · 01-14
盟科药业（688373.SH）聘任卢亮为副总经理、郭萃为财务负责人
盟科药业（688373）变更证券事务代表，奉竹女士接任
中金财经 · 01-14
盟科药业（688373）变更证券事务代表，奉竹女士接任
盟科药业拟补选王星海为董事 完善公司治理结构
中金财经 · 01-14
盟科药业拟补选王星海为董事 完善公司治理结构
盟科药业（688373）披露2023年限制性股票激励计划部分归属期符合归属条件，1月13日股价上涨0.3%
证券之星 · 01-13
盟科药业（688373）披露2023年限制性股票激励计划部分归属期符合归属条件，1月13日股价上涨0.3%
1月9日盟科药业发布公告，股东减持332.53万股
证券之星 · 01-09
1月9日盟科药业发布公告，股东减持332.53万股
1月7日盟科药业发布公告，股东减持655.61万股
证券之星 · 01-07
1月7日盟科药业发布公告，股东减持655.61万股
盟科药业：股东盟科香港拟减持不超3%股份
证券之星 · 01-06
盟科药业：股东盟科香港拟减持不超3%股份
盟科药业（688373）7952.35万股限售股将于1月5日解禁，占总股本12.13%
证券之星 · 01-05
盟科药业（688373）7952.35万股限售股将于1月5日解禁，占总股本12.13%
每周股票复盘：盟科药业（688373）董事李峙乐因个人原因离任
证券之星 · 01-02
每周股票复盘：盟科药业（688373）董事李峙乐因个人原因离任
盟科药业董事兼首席财务官李峙乐因个人原因辞职
中金财经 · 01-01
盟科药业董事兼首席财务官李峙乐因个人原因辞职
盟科药业（688373）披露董事、高级管理人员离任公告，12月31日股价上涨1.0%
证券之星 · 2025-12-31
盟科药业（688373）披露董事、高级管理人员离任公告，12月31日股价上涨1.0%
每周股票复盘：盟科药业（688373）12.13%限售股将解禁
证券之星 · 2025-12-28
每周股票复盘：盟科药业（688373）12.13%限售股将解禁
盟科药业（688373）披露首次公开发行部分限售股上市流通公告，12月23日股价下跌1.95%
证券之星 · 2025-12-23
盟科药业（688373）披露首次公开发行部分限售股上市流通公告，12月23日股价下跌1.95%
12月4日盟科药业发布公告，股东减持73.56万股
证券之星 · 2025-12-04
12月4日盟科药业发布公告，股东减持73.56万股
每周股票复盘：盟科药业（688373）终止向特定对象发行股票
证券之星 · 2025-11-23
每周股票复盘：盟科药业（688373）终止向特定对象发行股票
加载更多
公司概况
公司名称：
上海盟科药业股份有限公司
所属行业：
医药制造业
上市日期：
2022-08-05
主营业务：
上海盟科药业股份有限公司的主营业务是新药研发，并采用MAH模式委托有资质的原料药和制剂生产企业进行生产。公司的主要产品是MRX-1康替唑胺片、MRX-4、MRX-8、MRX-5。
发行价格：
8.16
{"stockData":{"symbol":"688373","market":"SH","secType":"STK","nameCN":"盟科药业","latestPrice":6.44,"timestamp":1770690754000,"preClose":6.36,"halted":0,"volume":2250342,"delay":0,"changeRate":0.0126,"floatShares":606000000,"shares":656000000,"eps":-0.5227,"marketStatus":"交易中","change":0.08,"latestTime":"02-10 10:32:34","open":6.36,"high":6.44,"low":6.32,"amount":14378500,"amplitude":0.0189,"askPrice":6.44,"askSize":342,"bidPrice":6.43,"bidSize":223,"shortable":0,"etf":0,"ttmEps":-0.5227,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1770694200000},"marketStatusCode":2,"adr":0,"adjPreClose":6.36,"symbolType":"stock_kcb","openAndCloseTimeList":[[1770687000000,1770694200000],[1770699600000,1770706800000]],"highLimit":7,"lowLimit":5.72,"ibTradeSell":true,"ibTradeBuySell":false,"totalEquity":656228380,"isCdr":false,"pbRate":16.2,"roa":"--","roe":"--","epsLYR":-0.67,"committee":-0.15058,"marketValue":4226000000,"turnoverRate":0.0037,"status":0,"floatMarketCap":3900000000},"requestUrl":"/m/hq/s/688373","defaultTab":"news","newsList":[{"id":"2608070396","title":"每周股票复盘：盟科药业（688373）MRX-5获美临床试验许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2608070396","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608070396?lang=zh_cn&edition=full","pubTime":"2026-02-01 03:51","pubTimestamp":1769889069,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，盟科药业报收于6.34元，较上周的6.56元下跌3.35%。本周，盟科药业1月26日盘中最高价报6.78元。本周关注点来自公司公告汇总：MRX-5片获USFDA批准在美开展IIa期临床试验。来自公司公告汇总：盟科药业完成限制性股票激励计划归属，新增622,889股股份上市。上海盟科药业股份有限公司完成2023年限制性股票激励计划首次授予部分第二个归属期及预留授予部分第一个归属期的股份登记工作。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020100001350.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688373","BK0239"],"gpt_icon":0},{"id":"2606080792","title":"盟科药业：MRX-5片获美国FDA批准开展临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2606080792","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606080792?lang=zh_cn&edition=full","pubTime":"2026-01-28 18:20","pubTimestamp":1769595631,"startTime":"0","endTime":"0","summary":"盟科药业(688373.SH)公告称，公司全资子公司MicuRx Pharmaceuticals, Inc.收到美国食品药品监督管理局的通知，公司自主研发的抗菌新药MRX-5片的临床试验申请已获得批准，可在美国开展临床试验。MRX-5片用于治疗脓肿分枝杆菌复合群感染引起的非空洞性肺病，属于新型治疗非结核分枝杆菌感染药物，具有良好的抗菌活性和安全性。该试验为随机、双盲、安慰剂对照、多中心IIa期研究。新药研发存在不确定性，对公司未来业务开拓和经营业绩的影响存在不确定性。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012800032578.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688373","BK0239"],"gpt_icon":0},{"id":"2606232232","title":"每周股票复盘：盟科药业（688373）预计2025年亏损收窄至2.25亿至2.65亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2606232232","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606232232?lang=zh_cn&edition=full","pubTime":"2026-01-25 03:00","pubTimestamp":1769281233,"startTime":"0","endTime":"0","summary":"截至2026年1月23日收盘，盟科药业报收于6.56元，较上周的6.53元上涨0.46%。本周，盟科药业1月23日盘中最高价报6.57元。本周关注点业绩披露要点：盟科药业预计2025年归属净利润亏损2.25亿元至2.65亿元，同比亏损减少39.87%到48.95%。预计2025年全年营业收入为1.35亿元至1.55亿元。公司公告汇总上海盟科药业股份有限公司预计2025年年度实现营业收入约为13,500.00万元到15,500.00万元，同比增长3.63%至18.98%；归属于母公司所有者的净利润预计为-26,500.00万元到-22,500.00万元，同比亏损减少39.87%到48.95%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012500000997.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688373","BK0239"],"gpt_icon":0},{"id":"2605409810","title":"盟科药业（688373）披露2025年年度业绩预告，1月23日股价上涨1.86%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605409810","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605409810?lang=zh_cn&edition=full","pubTime":"2026-01-23 22:54","pubTimestamp":1769180055,"startTime":"0","endTime":"0","summary":"截至2026年1月23日收盘，盟科药业报收于6.56元，较前一交易日上涨1.86%，最新总市值为43.01亿元。该股当日开盘6.43元，最高6.57元，最低6.4元，成交额达6023.9万元，换手率为1.53%。近日，上海盟科药业股份有限公司发布2025年年度业绩预告。公告显示，公司预计2025年年度实现营业收入约为13,500.00万元到15,500.00万元，同比增长3.63%至18.98%；归属于母公司所有者的净利润预计为-26,500.00万元到-22,500.00万元，同比亏损减少39.87%到48.95%。本次业绩预告未经注册会计师审计。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012300043494.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688373","BK0239"],"gpt_icon":0},{"id":"2603124476","title":"盟科药业（688373）披露股东减持股份计划公告，1月14日股价上涨0.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603124476","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603124476?lang=zh_cn&edition=full","pubTime":"2026-01-14 22:42","pubTimestamp":1768401734,"startTime":"0","endTime":"0","summary":"截至2026年1月14日收盘，盟科药业报收于6.75元，较前一交易日上涨0.45%，最新总市值为44.25亿元。公司近日发布公告称，截至公告披露日，Best Idea持有公司7.91%股份，JSR持有4.36%，GP TMT持有2.64%。股东Best Idea计划减持不超过公司总股本3%的股份，JSR及GP TMT作为一致行动人合计减持不超过公司总股本3%的股份，减持方式为集中竞价交易和大宗交易，减持期间为2026年2月5日至2026年5月4日，减持原因为资金需求，股份来源为IPO前取得。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011400041617.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688373","BK0239"],"gpt_icon":0},{"id":"2603596296","title":"盟科药业（688373.SH）聘任卢亮为副总经理、郭萃为财务负责人","url":"https://stock-news.laohu8.com/highlight/detail?id=2603596296","media":"中金财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603596296?lang=zh_cn&edition=full","pubTime":"2026-01-14 08:04","pubTimestamp":1768349055,"startTime":"0","endTime":"0","summary":"中访网数据 上海盟科药业股份有限公司于2026年1月12日召开第二届董事会第二十四次会议，审议通过了关于调整高级管理人员的议案。根据公司经营管理和组织调整的战略需要，董事会同意聘任卢亮先生为公司副总经理，聘任郭萃女士为公司财务负责人。卢亮先生自2016年起在公司任职，历任质量保证部经理、总监及质量总监，并曾担任公司职工代表监事、监事会主席。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20260114/31939250.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0239","688373"],"gpt_icon":0},{"id":"2603659608","title":"盟科药业（688373）变更证券事务代表，奉竹女士接任","url":"https://stock-news.laohu8.com/highlight/detail?id=2603659608","media":"中金财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603659608?lang=zh_cn&edition=full","pubTime":"2026-01-14 08:04","pubTimestamp":1768349054,"startTime":"0","endTime":"0","summary":"中访网数据 上海盟科药业股份有限公司于2026年1月12日召开第二届董事会第二十四次会议，审议通过了变更证券事务代表的议案。原证券事务代表聂安娜女士因个人工作调整原因离任。董事会同意聘任奉竹女士为公司新任证券事务代表，任期自董事会审议通过之日起至第二届董事会任期届满之日止。奉竹女士曾任职于上海第一医药股份有限公司，担任过证券事务代表等职务，并已取得科创板董事会秘书任职培训证明。此次人事变动为公司正常人事调整，旨在保障公司董事会办公室相关工作的顺利衔接与开展。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20260114/31939248.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0239","161027","688373"],"gpt_icon":0},{"id":"2603596706","title":"盟科药业拟补选王星海为董事 完善公司治理结构","url":"https://stock-news.laohu8.com/highlight/detail?id=2603596706","media":"中金财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603596706?lang=zh_cn&edition=full","pubTime":"2026-01-14 08:04","pubTimestamp":1768349052,"startTime":"0","endTime":"0","summary":"中访网数据 上海盟科药业股份有限公司于2026年1月12日召开第二届董事会第二十四次会议，审议通过了关于补选公司董事的议案。董事会同意提名公司现任副总经理、高级副总裁兼首席技术官王星海先生为公司第二届董事会非独立董事候选人。 若王星海先生经股东大会选举通过，其董事任期将自股东大会审议通过之日起至公司第二届董事会届满之日止。此次董事补选旨在完善公司治理结构，保障董事会工作的连续性和稳定性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20260114/31939243.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["688373","BK0239"],"gpt_icon":0},{"id":"2603638135","title":"盟科药业（688373）披露2023年限制性股票激励计划部分归属期符合归属条件，1月13日股价上涨0.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603638135","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603638135?lang=zh_cn&edition=full","pubTime":"2026-01-13 22:36","pubTimestamp":1768314974,"startTime":"0","endTime":"0","summary":"截至2026年1月13日收盘，盟科药业报收于6.72元，较前一交易日上涨0.3%，最新总市值为44.06亿元。该股当日开盘6.68元，最高6.86元，最低6.67元，成交额达1.24亿元，换手率为3.02%。近日，上海盟科药业股份有限公司发布公告称，2023年限制性股票激励计划首次授予部分第二个归属期及预留授予部分第一个归属期的归属条件已成就。公司2024年度营业收入为1.30亿元，IND申请受理1个，公司层面业绩考核归属系数为50%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011300042512.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688373"],"gpt_icon":0},{"id":"2602532489","title":"1月9日盟科药业发布公告，股东减持332.53万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2602532489","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602532489?lang=zh_cn&edition=full","pubTime":"2026-01-09 18:01","pubTimestamp":1767952894,"startTime":"0","endTime":"0","summary":"证券之星消息，1月9日盟科药业发布公告《盟科药业:上海盟科药业股份有限公司关于股东减持计划时间届满暨减持股份结果且权益变动触及1%刻度的公告》，其股东GP TMT Holdings Limited、JSR Limited于2025年10月9日至2026年1月8日间合计减持332.53万股，占公司目前总股本的0.5072%，变动期间该股股价下跌27.88%，截止1月8日收盘报6.57元。股东增减持详情见下表：根据盟科药业2025年三季报公布的十大股东详情如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010900029698.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688373","BK0239"],"gpt_icon":0},{"id":"2601790338","title":"1月7日盟科药业发布公告，股东减持655.61万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2601790338","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601790338?lang=zh_cn&edition=full","pubTime":"2026-01-07 18:01","pubTimestamp":1767780074,"startTime":"0","endTime":"0","summary":"证券之星消息，1月7日盟科药业发布公告《盟科药业:上海盟科药业股份有限公司持股5%以上股东权益变动触及1%刻度的提示性公告》，其股东Best Idea International Limited于2025年10月9日至2026年1月6日间合计减持655.61万股，占公司目前总股本的1.0%，变动期间该股股价下跌30.19%，截止1月6日收盘报6.36元。股东增减持详情见下表：根据盟科药业2025年三季报公布的十大股东详情如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010700028469.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688373","BK0239"],"gpt_icon":0},{"id":"2601892655","title":"盟科药业：股东盟科香港拟减持不超3%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2601892655","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601892655?lang=zh_cn&edition=full","pubTime":"2026-01-06 20:31","pubTimestamp":1767702666,"startTime":"0","endTime":"0","summary":"盟科药业(688373.SH)公告称，股东MicuRx（HK）Limited（简称“盟科香港”）计划通过集中竞价和大宗交易方式减持公司股份不超过1,966.82万股，占公司总股本的3%。其中集中竞价减持不超过655.61万股，大宗交易减持不超过1,311.21万股。减持原因为满足外籍股东和员工个人资金需求，减持期间为2026年1月28日至2026年4月27日。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010600039256.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688373"],"gpt_icon":0},{"id":"2601019020","title":"盟科药业（688373）7952.35万股限售股将于1月5日解禁，占总股本12.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601019020","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601019020?lang=zh_cn&edition=full","pubTime":"2026-01-05 08:02","pubTimestamp":1767571328,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息整理，盟科药业于1月5日将有7952.35万股限售股份解禁，为公司首发原股东限售股份，占公司总股本12.13%。最近一年内，该股累计解禁1.59亿股，占总股本的24.32%。本次解禁后，公司还有5059.05万股限售股份，占总股本7.72%。盟科药业主营业务：以治疗感染性疾病为核心,拥有全球自主知识产权和国际竞争力的创新药企业,致力于发现、开发和商业化针对未满足临床需求的创新药物。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010500002383.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688373","BK0239"],"gpt_icon":0},{"id":"2600039963","title":"每周股票复盘：盟科药业（688373）董事李峙乐因个人原因离任","url":"https://stock-news.laohu8.com/highlight/detail?id=2600039963","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600039963?lang=zh_cn&edition=full","pubTime":"2026-01-02 04:06","pubTimestamp":1767297974,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，盟科药业报收于6.08元，较上周的6.16元下跌1.3%。本周，盟科药业12月22日盘中最高价报6.2元。公司公告汇总上海盟科药业股份有限公司董事会近日收到董事、副总经理、首席财务官李峙乐先生递交的书面辞职报告，因个人原因，李峙乐先生辞去公司董事、董事会提名委员会委员、副总经理、首席财务官职务，辞职自送达董事会之日起生效。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010200001216.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688373","BK0239"],"gpt_icon":0},{"id":"2600856080","title":"盟科药业董事兼首席财务官李峙乐因个人原因辞职","url":"https://stock-news.laohu8.com/highlight/detail?id=2600856080","media":"中金财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600856080?lang=zh_cn&edition=full","pubTime":"2026-01-01 12:21","pubTimestamp":1767241265,"startTime":"0","endTime":"0","summary":"中访网数据 上海盟科药业股份有限公司于2026年1月1日发布公告，公司董事、副总经理、首席财务官李峙乐先生因个人原因，已于近日递交书面辞职报告，辞去其在上市公司担任的全部职务，包括董事、董事会提名委员会委员、副总经理及首席财务官。公司表示将尽快完成董事补选及财务负责人聘任工作。截至公告日，李峙乐先生直接持有公司2,636,714股股份，并通过境外架构间接持有公司股份，离任后其将继续遵守相关股份减持的承诺与规定。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20260101/31910001.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["688373","BK0239"],"gpt_icon":0},{"id":"2595777246","title":"盟科药业（688373）披露董事、高级管理人员离任公告，12月31日股价上涨1.0%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595777246","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595777246?lang=zh_cn&edition=full","pubTime":"2025-12-31 22:31","pubTimestamp":1767191475,"startTime":"0","endTime":"0","summary":"截至2025年12月31日收盘，盟科药业报收于6.04元，较前一交易日上涨1.0%，最新总市值为39.6亿元。该股当日开盘6.03元，最高6.04元，最低5.95元，成交额达2569.8万元，换手率为0.82%。因个人原因，李峙乐先生辞去公司董事、董事会提名委员会委员、副总经理、首席财务官职务，辞职自送达董事会之日起生效。公告显示，公司董事会正常运作及经营管理不会因李峙乐先生的辞职而受到影响，后续将尽快完成相关补选及聘任工作。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123100044995.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688373","BK0239"],"gpt_icon":0},{"id":"2594624799","title":"每周股票复盘：盟科药业（688373）12.13%限售股将解禁","url":"https://stock-news.laohu8.com/highlight/detail?id=2594624799","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594624799?lang=zh_cn&edition=full","pubTime":"2025-12-28 05:10","pubTimestamp":1766869821,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，盟科药业报收于6.08元，较上周的6.16元下跌1.3%。本周，盟科药业12月22日盘中最高价报6.2元。本周关注点公司公告汇总：盟科药业12.13%首发前限售股将于2026年1月5日解禁上市。公司公告汇总上海盟科药业股份有限公司首次公开发行部分限售股将于2026年1月5日上市流通，本次上市流通数量为79,523,500股，占公司总股本的12.13%。上述股东均已履行股份锁定及相关承诺，保荐机构中国国际金融股份有限公司对本次解禁无异议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122800001390.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688373"],"gpt_icon":0},{"id":"2593998194","title":"盟科药业（688373）披露首次公开发行部分限售股上市流通公告，12月23日股价下跌1.95%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593998194","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593998194?lang=zh_cn&edition=full","pubTime":"2025-12-23 17:58","pubTimestamp":1766483928,"startTime":"0","endTime":"0","summary":"截至2025年12月23日收盘，盟科药业报收于6.04元，较前一交易日下跌1.95%，最新总市值为39.6亿元。该股当日开盘6.16元，最高6.16元，最低6.03元，成交额达4100.09万元，换手率为1.29%。公司近日发布公告称，上海盟科药业股份有限公司首次公开发行部分限售股将于2026年1月5日上市流通。本次上市流通数量为79,523,500股，占公司总股本的12.13%。涉及股东包括Genie Pharma、盟科香港及新沂优迈，上述股东均为首发前限售股股东。保荐机构中国国际金融股份有限公司对本次解禁无异议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122300029390.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688373","BK0239"],"gpt_icon":0},{"id":"2588891998","title":"12月4日盟科药业发布公告，股东减持73.56万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2588891998","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588891998?lang=zh_cn&edition=full","pubTime":"2025-12-04 20:01","pubTimestamp":1764849683,"startTime":"0","endTime":"0","summary":"证券之星消息，12月4日盟科药业发布公告《盟科药业:上海盟科药业股份有限公司股东减持计划时间届满暨减持股份结果公告》，其股东MicuRx(HK) Limited于2025年9月5日至2025年12月4日间合计减持73.56万股，占公司目前总股本的0.1122%，变动期间该股股价下跌23.38%，截止12月4日收盘报6.13元。股东增减持详情见下表：根据盟科药业2025年三季报公布的十大股东详情如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120400034874.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688373","BK0239"],"gpt_icon":0},{"id":"2585108038","title":"每周股票复盘：盟科药业（688373）终止向特定对象发行股票","url":"https://stock-news.laohu8.com/highlight/detail?id=2585108038","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585108038?lang=zh_cn&edition=full","pubTime":"2025-11-23 01:59","pubTimestamp":1763834347,"startTime":"0","endTime":"0","summary":"截至2025年11月21日收盘，盟科药业报收于6.33元，较上周的7.39元下跌14.34%。本周，盟科药业11月17日盘中最高价报7.42元。本周关注点公司公告汇总：盟科药业终止向南京海鲸药业发行163,901,373股股份的计划。上海盟科药业股份有限公司于2025年11月15日召开董事会，审议通过终止向特定对象发行股票事项。此前公司拟向南京海鲸药业发行163,901,373股股份募集资金103,257.86万元，并获股东大会批准。本次终止不会对公司生产经营造成实质性影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112300000376.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688373"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1770690769643,"stockEarnings":[{"period":"1week","weight":0.0392},{"period":"1month","weight":-0.055},{"period":"3month","weight":-0.1311},{"period":"6month","weight":-0.209},{"period":"1year","weight":0.2161},{"period":"ytd","weight":0.053}],"compareEarnings":[{"period":"1week","weight":0.0267},{"period":"1month","weight":0.0006},{"period":"3month","weight":0.0301},{"period":"6month","weight":0.1194},{"period":"1year","weight":0.248},{"period":"ytd","weight":0.0389}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海盟科药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"16492人(较上一季度增加14.18%)","perCapita":"36723股","listingDate":"2022-08-05","address":"上海市浦东新区中国(上海)自由贸易试验区爱迪生路53号1幢1-4层101、2幢","registeredCapital":"65622万元","survey":" 上海盟科药业股份有限公司的主营业务是新药研发，并采用MAH模式委托有资质的原料药和制剂生产企业进行生产。公司的主要产品是MRX-1康替唑胺片、MRX-4、MRX-8、MRX-5。","listedPrice":8.16},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"盟科药业(688373)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供盟科药业(688373)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"盟科药业,688373,盟科药业股票,盟科药业股票老虎,盟科药业股票老虎国际,盟科药业行情,盟科药业股票行情,盟科药业股价,盟科药业股市,盟科药业股票价格,盟科药业股票交易,盟科药业股票购买,盟科药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"盟科药业(688373)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供盟科药业(688373)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}